1-20 of 23
Jeffrey S. Weber
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance

Ankita Mitra, Brian Thompson, Ann Strange, Carol M. Amato, Melinda Vassallo, Igor Dolgalev, Jonathan Hester-McCullough, Tomoaki Muramatsu, Diana Kimono, Amrutesh S. Puranik, Jeffrey S. Weber, David Woods
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF14.
https://doi.org/10.1158/1078-0432.CCR-23-0653
Published: 07 September 2023
View article titled, A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
Open the PDF for A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

MacLean S. Hall, John E. Mullinax, Cheryl A. Cox, Amy M. Hall, Matthew S. Beatty, Jamie Blauvelt, Patrick Innamarato, Luz Nagle, Holly Branthoover, Doris Wiener, Benjamin Schachner, Alberto J. Martinez, Allison D. Richards, Carolyn J. Rich, Marjorie Colón Colón, Michael J. Schell, Jamie K. Teer, Nikhil I. Khushalani, Jeffrey S. Weber, James J. Mulé, Vernon K. Sondak, Shari Pilon-Thomas, Amod A. Sarnaik
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5317–5329.
https://doi.org/10.1158/1078-0432.CCR-22-2103
Published: 15 December 2022
View article titled, Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Open the PDF for Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Intratumoral Therapy to Make a “Cold” Tumor “Hot”: The Jury Is Still Out

Salman R. Punekar, Jeffrey S. Weber
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (23): 5007–5009.
https://doi.org/10.1158/1078-0432.CCR-22-2427
Published: 01 December 2022
View article titled, Intratumoral Therapy to Make a “Cold” Tumor “Hot”: The Jury Is Still Out
Open the PDF for Intratumoral Therapy to Make a “Cold” Tumor “Hot”: The Jury Is Still Out in another window
Journal Articles

Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade

Paul Johannet, Wenke Liu, David Fenyo, Megan Wind-Rotolo, Michelle Krogsgaard, Janice M. Mehnert, Jeffrey S. Weber, Judy Zhong, Iman Osman
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 4121–4130.
https://doi.org/10.1158/1078-0432.CCR-22-0404
Published: 15 September 2022
View article titled, Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
Open the PDF for Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade in another window
Includes: Supplementary data
Journal Articles

A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors

Fyza Y. Shaikh, James R. White, Joell J. Gills, Taiki Hakozaki, Corentin Richard, Bertrand Routy, Yusuke Okuma, Mykhaylo Usyk, Abhishek Pandey, Jeffrey S. Weber, Jiyoung Ahn, Evan J. Lipson, Jarushka Naidoo, Drew M. Pardoll, Cynthia L. Sears
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2571–2583.
https://doi.org/10.1158/1078-0432.CCR-20-4834
Published: 01 May 2021
View article titled, A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors
Open the PDF for A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma

Paul Johannet, Nicolas Coudray, Douglas M. Donnelly, George Jour, Irineu Illa-Bochaca, Yuhe Xia, Douglas B. Johnson, Lee Wheless, James R. Patrinely, Sofia Nomikou, David L. Rimm, Anna C. Pavlick, Jeffrey S. Weber, Judy Zhong, Aristotelis Tsirigos, Iman Osman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (1): 131–140.
https://doi.org/10.1158/1078-0432.CCR-20-2415
Published: 04 January 2021
View article titled, Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma
Open the PDF for Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells

Junya Ichikawa, Tatsuya Yoshida, Ariel Isser, Andressa S. Laino, Melinda Vassallo, David Woods, Sojung Kim, Mathias Oelke, Kristi Jones, Jonathan P. Schneck, Jeffrey S. Weber
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3384–3396.
https://doi.org/10.1158/1078-0432.CCR-19-3487
Published: 01 July 2020
View article titled, Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells
Open the PDF for Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells in another window
Includes: Supplementary data
Journal Articles

TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?

Jeffrey S. Weber, Michael A. Postow
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2085–2086.
https://doi.org/10.1158/1078-0432.CCR-20-0387
Published: 01 May 2020
View article titled, TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?
Open the PDF for TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly? in another window
Journal Articles

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

Cigdem Atay, Taekyoung Kwak, Sergio Lavilla-Alonso, Laxminarasimha Donthireddy, Allison Richards, Valerie Moberg, Shari Pilon-Thomas, Michael Schell, Jane L. Messina, Vito W. Rebecca, Min Xiao, Jiufeng Tan, Gao Zhang, Jeffrey S. Weber, Meenhard Herlyn, Amod A. Sarnaik, Dmitry I. Gabrilovich
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (9): 2783–2794.
https://doi.org/10.1158/1078-0432.CCR-18-2725
Published: 01 May 2019
View article titled, BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells
Open the PDF for BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells in another window
Includes: Supplementary data
Journal Articles

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma

David M. Woods, Rupal Ramakrishnan, Andressa S. Laino, Anders Berglund, Kelly Walton, Brian C. Betts, Jeffrey S. Weber
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6236–6247.
https://doi.org/10.1158/1078-0432.CCR-18-1100
Published: 13 December 2018
View article titled, Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma
Open the PDF for Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 6098.
https://doi.org/10.1158/1078-0432.CCR-18-3340
Published: 03 December 2018
View article titled, Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Journal Articles

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma

Zeynep Eroglu, Y. Ann Chen, Geoffrey T. Gibney, Jeffrey S. Weber, Ragini R. Kudchadkar, Nikhil I. Khushalani, Joseph Markowitz, Andrew S. Brohl, Leticia F. Tetteh, Howida Ramadan, Gina Arnone, Jiannong Li, Xiuhua Zhao, Ritin Sharma, Lancia N.F. Darville, Bin Fang, Inna Smalley, Jane L. Messina, John M. Koomen, Vernon K. Sondak, Keiran S.M. Smalley
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (22): 5516–5524.
https://doi.org/10.1158/1078-0432.CCR-18-0565
Published: 15 November 2018
View article titled, Combined BRAF and HSP90 Inhibition in Patients with Unresectable <em>BRAF</em><sup>V600E</sup>-Mutant Melanoma
Open the PDF for Combined BRAF and HSP90 Inhibition in Patients with Unresectable <em>BRAF</em><sup>V600E</sup>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (20): 4960–4967.
https://doi.org/10.1158/1078-0432.CCR-17-2386
Published: 15 October 2018
View article titled, Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Includes: Supplementary data
Journal Articles

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Morganna Freeman-Keller, Youngchul Kim, Heather Cronin, Allison Richards, Geoffrey Gibney, Jeffrey S. Weber
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 886–894.
https://doi.org/10.1158/1078-0432.CCR-15-1136
Published: 14 February 2016
View article titled, Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Open the PDF for Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, Rene Gonzalez, Jose Lutzky, Steven J. O'Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil Ramaiya, Anita Giobbie-Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2289–2296.
https://doi.org/10.1158/1078-0432.CCR-14-1630
Published: 14 May 2015
View article titled, Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Open the PDF for Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition in another window
Includes: Supplementary data
Journal Articles

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

Geoffrey T. Gibney, Ragini R. Kudchadkar, Ronald C. DeConti, Melissa S. Thebeau, Maria P. Czupryn, Leticia Tetteh, Cabell Eysmans, Allison Richards, Michael J. Schell, Kate J. Fisher, Christine E. Horak, H. David Inzunza, Bin Yu, Alberto J. Martinez, Ibrahim Younos, Jeffrey S. Weber
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 712–720.
https://doi.org/10.1158/1078-0432.CCR-14-2468
Published: 16 February 2015
View article titled, Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
Open the PDF for Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma in another window
Journal Articles

Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

Yan Feng, Amit Roy, Eric Masson, Tai-Tsang Chen, Rachel Humphrey, Jeffrey S. Weber
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (14): 3977–3986.
https://doi.org/10.1158/1078-0432.CCR-12-3243
Published: 15 July 2013
View article titled, Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
Open the PDF for Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

Kim H.T. Paraiso, H. Eirik Haarberg, Elizabeth Wood, Vito W. Rebecca, Y. Ann Chen, Yun Xiang, Antoni Ribas, Roger S. Lo, Jeffrey S. Weber, Vernon K. Sondak, Jobin K. John, Amod A. Sarnaik, John M. Koomen, Keiran S.M. Smalley
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2502–2514.
https://doi.org/10.1158/1078-0432.CCR-11-2612
Published: 30 April 2012
View article titled, The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
Open the PDF for The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms in another window
Includes: Supplementary data
Journal Articles

Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial

Antoni Ribas, Jeffrey S. Weber, Bartosz Chmielowski, Begonya Comin-Anduix, David Lu, Michael Douek, Nagesh Ragavendra, Steve Raman, Elizabeth Seja, Darlene Rosario, Sabrina Miles, David C. Diamond, Zhiyong Qiu, Mihail Obrocea, Adrian Bot
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (9): 2987–2996.
https://doi.org/10.1158/1078-0432.CCR-10-3272
Published: 01 May 2011
View article titled, Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial
Open the PDF for Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

Amod A. Sarnaik, Bin Yu, Daohai Yu, Dawn Morelli, MacLean Hall, Dilip Bogle, Lulu Yan, Stephan Targan, Jolie Solomon, Geoff Nichol, Michael Yellin, Jeffrey S. Weber
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 896–906.
https://doi.org/10.1158/1078-0432.CCR-10-2463
Published: 15 February 2011
View article titled, Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
Open the PDF for Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma in another window